Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 456906 receptor occupancy PET/MRI study versus semaglutide in adults with obesity
NL-OMON56752Phase 1Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- May 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of survodutide and semaglutide in obesity (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Percentage of glucagon receptor occupancy in the liver. Planned start May 2024; status: not yet recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NL-OMON56752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56752.